Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries (BIO-OSCAR First)

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Subject ≥18 years old 2. Subject has provided written willing to sign a consent form 3. Subject has Rutherford classification 2 to 6 4. Reference vessel diameter ≥2 and ≤7 mm 5. Target lesion(s) has stenosis \>70% by visual assessment 6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion. Above the knee (ATK) group: 7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau) 8. At least one below-knee artery patent to the ankle 9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications. Below the knee (BTK) group: 10. Target lesions involve arteries below the tibial plateau 11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications Who Should NOT Join This Trial: 1. Subject has a single target lesion that involves both ATK and BTK segments. 2. Subject not suitable for receiving endovascular procedures of lower limb arteries. 3. Prior planned major amputation in the target limb (i.e., above the ankle). 4. Subject with previous bypass surgery of target vessel. 5. History of any open surgical procedure within the past 30 days. 6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb. Note: The inflow vessels can be treated on the day of the procedure. 7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis). 8. Subject under dialysis. ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Subject ≥18 years old 2. Subject has provided written informed consent 3. Subject has Rutherford classification 2 to 6 4. Reference vessel diameter ≥2 and ≤7 mm 5. Target lesion(s) has stenosis \>70% by visual assessment 6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion. Above the knee (ATK) group: 7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau) 8. At least one below-knee artery patent to the ankle 9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications. Below the knee (BTK) group: 10. Target lesions involve arteries below the tibial plateau 11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications Exclusion Criteria: 1. Subject has a single target lesion that involves both ATK and BTK segments. 2. Subject not suitable for receiving endovascular procedures of lower limb arteries. 3. Prior planned major amputation in the target limb (i.e., above the ankle). 4. Subject with previous bypass surgery of target vessel. 5. History of any open surgical procedure within the past 30 days. 6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb. Note: The inflow vessels can be treated on the day of the procedure. 7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis). 8. Subject under dialysis. 9. Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached. 10. Subject lacking capacity to provide informed consent. 11. Subject under judicial protection, tutorship, or curatorship (for France only).

Treatments Being Tested

DEVICE

Oscar Peripheral Multifunctional Catheter

Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon. Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU).

Locations (16)

LKH Univ. -Klinikum Graz, Ambulanz für Angiologie
Graz, Austria
Onze Lieve Vrouwziekenhuis
Aalst, Belgium
AZ Saint Blasius
Dendermonde, Belgium
ZOL Ziekenhuis Oost Limburg
Genk, Belgium
University Hospital Ghent
Ghent, Belgium
vzw AZ Groeninge
Kortrijk, Belgium
Hopital Saint Joseph
Paris, France
Karolinen-Hospital Arnsberg
Arnsberg, Germany
Sankt Gertrauden-Krankenhaus
Berlin, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Semmelweis University
Budapest, Hungary
Policlinico Abano Terme
Abano Terme, Italy
Azienda Usl Toscana sud est
Arezzo, Italy
ospedaliero-universitaria Senese
Siena, Italy
Hospital Universitario de Guadalajara
Guadalajara, Spain
Ospedale Regionale civico EOC di Lugano
Lugano, Switzerland